{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:41:32Z","timestamp":1792190492447,"version":"4.4.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jdsjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.jdermsci.2011.05.005","type":"journal-article","created":{"date-parts":[[2011,5,23]],"date-time":"2011-05-23T05:52:54Z","timestamp":1306129974000},"page":"154-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":188,"title":["Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)"],"prefix":"10.1016","volume":"63","author":[{"given":"Tsen-Fang","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Chen","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Szapary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Guzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuang-Kuang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang-Joong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Yoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee-Ho","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jai-Il","family":"Youn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdermsci.2011.05.005_bib0005","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0010","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMra041320","volume":"352","author":"Sch\u00f6n","year":"2005","journal-title":"Engl J Med"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0015","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1529-8019.2008.00170.x","article-title":"The psychosocial and occupational impact of chronic skin disease","volume":"21","author":"Hong","year":"2008","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0020","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/00128071-200506060-00005","article-title":"The psychosocial burden of psoriasis","volume":"6","author":"Kimball","year":"2005","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0025","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0733-8635(05)70376-4","article-title":"Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment","volume":"14","author":"Koo","year":"1996","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0030","first-page":"69","article-title":"Current status and prospect for psoriasis treatment in Taiwan","volume":"23","author":"Tsai","year":"2005","journal-title":"Dermatol Sinica"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0035","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.it.2004.03.006","article-title":"Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and \u201cType 1\u201d inflammatory gene expression","volume":"25","author":"Lew","year":"2004","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0040","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.2310\/7750.2009.00023","article-title":"Safety of conventional systemic agents and biologic agents in the treatment of psoriasis","volume":"13","author":"Bissonnette","year":"2009","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0045","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1365-2133.2008.08781.x","article-title":"Long-term data in the treatment of psoriasis","volume":"159","author":"Tha\u00e7i","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0050","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2174\/157339709789208615","article-title":"The use of biologics for psoriasis in Asia-Pacific region","volume":"5","author":"Tsai","year":"2009","journal-title":"Curr Rheumatol Rev"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0055","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1346-8138.2009.00748.x","article-title":"Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II\/III randomized controlled study","volume":"37","author":"Asahina","year":"2010","journal-title":"J Dermatol"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0060","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1346-8138.2008.00508.x","article-title":"Low-dose etanercept therapy in moderate to severe psoriasis in Korean","volume":"35","author":"Na","year":"2008","journal-title":"J Dermatol"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0065","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdermsci.2010.04.014","article-title":"Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial","volume":"59","author":"Torii","year":"2010","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0070","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/j.1468-3083.2007.02575.x","article-title":"Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderate-to-severe chronic plaque psoriasis in Taiwan: results of an open-label, single-arm, multicentre pilot study","volume":"22","author":"Huang","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0075","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1468-3083.2007.02430.x","article-title":"Clinical effectiveness and safety experience with efalizumab in the treatment of patients with moderate-to-severe plaque psoriasis in Taiwan: results of an open-label, single-arm pilot study","volume":"22","author":"Tsai","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0090","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S1074-7613(00)00070-4","article-title":"Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12","volume":"13","author":"Oppmann","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0095","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1046\/j.1523-1747.1998.00446.x","article-title":"Expression of interleukin-12 is increased in psoriatic skin","volume":"111","author":"Yawalkar","year":"1998","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0100","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1084\/jem.20030451","article-title":"Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris","volume":"199","author":"Lee","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0105","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.4049\/jimmunol.176.3.1908","article-title":"In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin","volume":"176","author":"Piskin","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0110","doi-asserted-by":"crossref","first-page":"7480","DOI":"10.4049\/jimmunol.162.12.7480","article-title":"IL-12, independently of IFN-\u03b3, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder","volume":"162","author":"Hong","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0115","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1074\/jbc.M207577200","article-title":"Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17","volume":"278","author":"Aggarwall","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0120","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nri1001","article-title":"Interleukin-12 and the regulation of innate resistance and adaptive immunity","volume":"3","author":"Trinchieri","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0125","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1365-2133.2006.07180.x","article-title":"Interleukin-12 production by monocytes from patients with psoriasis and its inhibition by ciclosporin A","volume":"154","author":"Tada","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0130","doi-asserted-by":"crossref","first-page":"e1000041","DOI":"10.1371\/journal.pgen.1000041","article-title":"A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci","volume":"4","author":"Liu","year":"2008","journal-title":"PLoS Genet"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0135","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00403-009-0986-y","article-title":"Genetic evidence for involvement of the IL23 pathway in Thai psoriatics","volume":"302","author":"Nair","year":"2010","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0140","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa062382","article-title":"A human interleukin-12\/23 monoclonal antibody for the treatment of psoriasis","volume":"356","author":"Krueger","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0145","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0150","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0155","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0160","unstructured":"Data on file. Centocor Research & Development."},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0165","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis: oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0170","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0175","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-2133.2009.09491.x","article-title":"Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial","volume":"162","author":"Lebwohl","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0180","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaad.2009.09.014","article-title":"Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial","volume":"63","author":"Langley","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0185","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2340\/00015555-0642","article-title":"Epidemiological study of psoriasis in the national health insurance database in Taiwan","volume":"89","author":"Chang","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0250","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdermsci.2011.03.002","article-title":"Epidemiology and comorbidities of psoriasis patients in a National Database in Taiwan","volume":"63","author":"Tsai","year":"2011","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0195","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1001\/jama.281.11.1014","article-title":"Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic","volume":"281","author":"Nolan","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0200","doi-asserted-by":"crossref","unstructured":"Chiu HY, Hsueh PR, Tsai TF. Clinical experience of QuantiFERON\u00ae-TB Gold testing in psoriasis patients treated with tumour necrosis factor blockers in Taiwan. Br J Dermatol; 2011;164:553-9.","DOI":"10.1111\/j.1365-2133.2010.10137.x"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0205","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jaad.2008.01.006","article-title":"National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening","volume":"58","author":"Kimball","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0210","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0215","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jaad.2006.08.040","article-title":"Prevalence of cardiovascular risk factors in patients with psoriasis","volume":"55","author":"Neimann","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0220","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jaad.2010.01.050","article-title":"Increased risk of acute myocardial infarction in patients with psoriasis: a 5-year population-based study in Taiwan","volume":"64","author":"Lin","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0225","unstructured":"Lebwohl M, Leonardi C, Griffiths CE, Prinz JC, Szapary PO, Yeilding N, et al. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. J Am Acad Dermatol; in press."},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0230","unstructured":"Gordon KB, Papp KA, Langley RG, Ho V, Kimball AB, Guzzo C, et al. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled Phase 2 and 3 clinical trials. J Am Acad Dermatol; in press."},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0235","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1365-2133.2011.10257.x","article-title":"Cardiovascular safety of ustekinumab in patients with moderate-to-severe psoriasis: results of integrated analyses of data from phase II and III clinical studies","volume":"164","author":"Reich","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0240","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jaad.2009.11.012","article-title":"Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations","volume":"63","author":"Lebwohl","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdermsci.2011.05.005_bib0245","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0091-7435(03)00119-1","article-title":"Prevalence of overweight and obesity and its associated factors: findings from National Nutrition and Health Survey in Taiwan, 1993\u20131996","volume":"37","author":"Lin","year":"2003","journal-title":"Prev Med"}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181111001538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181111001538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T04:47:45Z","timestamp":1760330865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181111001538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0923181111001538"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2011.05.005","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2011.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}